The global genotyping market is projected to reach USD 31.9 billion by 2023 from USD 11.8 billion in 2018, at a CAGR of 22.0%. Factors such as technological advancements, the decreasing prices of DNA sequencing, and the increasing incidence of genetic diseases are driving the growth of this market. The demand for genome analysis in plants and animal livestock, a rising focus on national sequencing projects to establish links between genetics and disease, and the growing application areas of genotyping are expected to provide growth opportunities for players operating in the genotyping market in the coming years. However, the high cost of equipment is expected to restrain the growth of this market during the forecast period.
Illumina (US), Thermo Fisher Scientific (US), QIAGEN (Netherlands), Agilent Technologies (US), Danaher Corporation (US), Roche Diagnostics (Switzerland), GE Healthcare (US), Fluidigm Corporation (US), PerkinElmer (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories (US), Pacific Biosciences of California (US), GENEWIZ (US), and Integrated DNA Technologies (US) are some key players in this market. These companies are focusing on increasing their presence in the high-growth markets through both organic as well as inorganic growth strategies such as product launches, approvals & enhancements; expansion; agreements, collaboration & partnerships; and acquisition.
To know about the assumptions considered for the study download the pdf brochure
Illumina is the leading player in the genotyping market. The company led the sequencing market with its flagship NGS platforms—iSeq 100 system (launched in January 2018), NovaSeq 6000, HiSeq Series, MiSeq Series, NextSeq 500, and HiSeq X Ten & HiSeq X Five. Illumina also provides reagents such as TruSeq sample preparation kits, TruSeq SBS sequencing kits, and other sequencing reagents, along with sequencing services such as whole-genome sequencing, human whole-exome sequencing, de novo sequencing, custom-targeted resequencing, gene expression using random-primed RNA sampling, and other related services. More than 54% of Illumina’s revenue generated from the US and over 22% comes from the European region. The company focuses on strengthening its position by entering into agreements and partnerships with other small players and launching new products to strengthen its product portfolio in the market. From 2015 to 2018 (July), the company launched more than 15 products and entered into 17 agreements, partnerships, and collaborations.
Thermo Fisher Scientific is the second-largest player in the global genotyping market in 2018. The firm’s leading position in this market is attributed to its wide product portfolio, which includes genomic profiling, PCR, and microarray analysis instruments & reagents. The company has a wide geographic presence spanning North America, Latin America, Europe, Africa, the Middle East, and the Asia Pacific. The company provides genotyping systems, namely, Ion PGM, Ion Proton, Ion GeneStudio S5 System, Axiom Genotyping Solution, GeneChip Scanner, and QuantStudio 3 Real-time PCR systems in the market. Thermo Fisher also provides sequencing reagents and services. In order to sustain its leading position in the market, the company focuses on launching new products and entering into partnerships and collaborations with other players in this market. Thermo Fisher also focuses on geographic expansion. In line with this, the firm has opened new GMP facilities in the US and South Korea in 2016. Moreover, the company aims to strengthen its presence in selected geographies in the Asia Pacific region.
Genotyping Assay Market by Technology (PCR, Sequencing, Microarray, Electrophoresis, MALDI-TOF), Application (Pharmacogenomics, Diagnostic Research, Animal Genetics, Agricultural Biotechnology), and Product - Global Forecast to 2023
Mr. Shelly Singh
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE